Drug Profile
Leptin gene therapy - Chiron Corporation
Latest Information Update: 15 Aug 2007
Price :
$50
*
At a glance
- Originator Chiron Corporation
- Class Gene therapies; Obesity therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetes mellitus; Obesity
Most Recent Events
- 22 Jan 1998 New profile
- 22 Jan 1998 Preclinical development for Diabetes mellitus in USA (IM)
- 22 Jan 1998 Preclinical development for Obesity in USA (IM)